Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation

Journal of Hepatology

Volumn 60, Issue 6, 2014, Pages 1127-1134

  Chen, Chien Hung ^a   Lin, Chih Lang ^b   Hu, Tsung Hui ^a   Hung, Chao Hung ^a   Tseng, Po Lin ^a   Wang, Jing Houng ^a   Chang, Juan Yu ^a   Lu, Sheng Nan ^a   Chien, Rong Nan ^b   Lee, Chuan Mo ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Basal core promoter mutation; Hepatic encephalopathy; Hepatitis B virus; Liver related mortality; MELD scores

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; CREATININE; HEPATITIS B VIRUS DNA; TELBIVUDINE; UNCLASSIFIED DRUG; VIRUS DNA; ANTIVIRUS AGENT; GUANINE;

ACUTE ON CHRONIC LIVER FAILURE; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BRAIN HEMORRHAGE; BRAIN METASTASIS; BREAST CANCER; CHRONIC HEPATITIS; CHRONIC LIVER FAILURE; COMPARATIVE STUDY; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; END STAGE LIVER DISEASE; FEMALE; FOLLOW UP; GENOTYPE; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SEPSIS; SEROCONVERSION; TREATMENT DURATION; TREATMENT RESPONSE; ACUTE DISEASE; ANTIVIRAL THERAPY; ASCITES; BACTERIAL PERITONITIS; CAUSE OF DEATH; DISEASE SEVERITY; DRUG WITHDRAWAL; HEART FAILURE; HEPATORENAL SYNDROME; INTERNATIONAL NORMALIZED RATIO; LUNG CANCER; MIDDLE AGED; MODEL FOR END STAGE LIVER DISEASE SCORE; SARCOMA; SENSITIVITY AND SPECIFICITY; SEVERE ACUTE EXACERBATION; SMALL INTESTINE CANCER; TERMINAL DISEASE; UNSPECIFIED SIDE EFFECT; VARICEAL HEMORRHAGE; VARICOSIS; ACUTE-ON-CHRONIC LIVER FAILURE; ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; CLINICAL TRIAL; GENETICS; HEPATITIS B, CHRONIC; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE; PROGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEVERITY OF ILLNESS INDEX;

ACUTE-ON-CHRONIC LIVER FAILURE; ADULT; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; END STAGE LIVER DISEASE; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 84901192746     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.02.013     Document Type: Article

References (42)

1. W.M. Lee Hepatitis B virus infection N Engl J Med 337 1997 1733 1745
2. D.S. Chen From hepatitis to hepatoma: lessons from type B viral hepatitis Science 262 1993 369 370
3. Y.F. Liaw Natural history of chronic hepatitis B virus infection and long-term outcome under treatment Liver Int 29 2009 100 107
4. C.M. Lee, S.N. Lu, C.S. Changchien, C.T. Yeh, T.T. Hsu, and J.H. Tang et al. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection Cancer 86 1999 1143 1150
5. A.S. Lok, and C.L. Lai Acute exacerbation in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology J Hepatol 10 1990 29 34
6. V.W. Wong, and H.L. Chan Severe acute exacerbation of chronic hepatitis B: a unique presentation of a common disease J Gastroenterol Hepatol 24 2009 1179 1186
7. Y.F. Liaw, N. Leung, J.H. Kao, T. Piratvisuth, E. Gane, and K.H. Han et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update Hepatol Int 2 2008 263 283
8. C.L. Lai, R.N. Chien, N.W. Leung, T.T. Chang, R. Guan, and D.I. Tai et al. A one-year trial of lamivudine for chronic hepatitis B N Engl J Med 339 1998 61 68
9. C.M. Lee, G.Y. Ong, S.N. Lu, J.H. Wang, C.A. Liao, and H.D. Tung et al. Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation J Hepatol 37 2002 669 674
10. Y.F. Liaw, J.J. Sung, W.C. Chow, G. Farrell, C.Z. Lee, and H. Yuen et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease N Engl J Med 351 2004 1521 1531
11. Y.F. Liaw, J.H. Kao, T. Piratvisuth, H.L.Y. Chan, R.N. Chien, and C.J. Liu et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update Hepatol Int 6 2012 531 561
12. A.S.F. Lok, and B.J. McMahon Chronic hepatitis B: update 2009 Hepatology 50 2009 1 36
13. EASL Clinical Practice Guidelines Management of chronic hepatitis B virus infection Eur Assoc Study Liver J Hepatol 57 2012 167 185
14. H.L. Chan, V.W. Wong, A.Y. Hui, S.W. Tsang, J.L. Chan, and H.Y. Chan et al. Long-term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B Antivir Ther 11 2006 465 471
15. V.W. Wong, G.L. Wong, S.W. Tsang, A.Y. Hui, A.M. Chim, and K.K. Yiu et al. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B Antivir Ther 13 2008 571 579
16. A. Tsubota, Y. Arase, Y. Suzuki, F. Suzuki, T. Hosaka, and N. Akuta et al. Benefit of lamivudine therapy and factors associated with clinical outcome in spontaneous severe acute exacerbation of chronic hepatitis B virus infection Intervirology 47 2004 335 341
17. A.S. Lok, C.L. Lai, N. Leung, G.B. Yao, Z.Y. Cui, and E.R. Schiff et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B Gastroenterology 125 2003 1714 1722
18. R.G. Gish, A.S. Lok, T.T. Chang, R.A. de Man, A. Gadano, and J. Sollano et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B Gastroenterology 33 2007 1437 1444
19. T.T. Chang, C.L. Lai, S.K. Yoon, S.S. Lee, H.S. Coelho, and F.J. Carrilho et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B Hepatology 51 2010 422 430
20. D.J. Tenney, R.E. Rose, C.J. Baldick, K.A. Pokornowski, B.J. Eggers, and J. Fang et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy Hepatology 49 2009 1503 1514
21. C.M. Lange, J. Bojunga, W.P. Hofmann, K. Wunder, U. Mihm, and S. Zeuzem et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function Hepatology 50 2009 2001 2006
22. V.W. Wong, G.L. Wong, K.K. Yiu, A.M. Chim, S.H. Chu, and H.Y. Chan et al. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B J Hepatol 54 2011 236 242
23. Y.C. Hsu, L.R. Mo, C.Y. Chang, D.S. Perng, C.H. Tseng, and G.H. Lo et al. Entecavir versus lamivudine in the treatment of chronic hepatitis B patients with hepatic decompensation Antivir Ther 17 2012 605 612
24. R.N. Chien, C.H. Lin, and Y.F. Liaw The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B J Hepatol 38 2003 322 327
25. I.S. Sheen, Y.F. Liaw, and D.I. Tai et al. Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis Gasteroenterology 89 1985 732 735
26. W.J. Jeng, I.S. Sheen, and Y.F. Liaw Hepatitis B virus DNA level predicts hepatic decompensation in patients with acute exacerbation of chronic hepatitis B Clin Gastroenterol Hepatol 8 2010 541 545
27. S.K. Sarin, A. Kumar, J.A. Almeida, Y.K. Chawla, S.T. Fan, and H. Garg et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL) Hepatol Int 3 2009 269 282
28. C.H. Chen, C.M. Lee, S.N. Lu, J.H. Wang, H.D. Tung, and C.H. Hung et al. Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy after biochemical breakthrough of YMDD mutants J Hepatol 41 2004 454 461
29. C.H. Chen, C.H. Hung, C.M. Lee, T.H. Hu, J.H. Wang, and J.C. Wang et al. Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients Gastroenterology 133 2007 1466 1474
30. C.H. Chen, C.M. Lee, S.N. Lu, C.S. Changchien, H.L. Eng, and C.M. Huang et al. Clinical significance of hepatitis B virus (HBV) genotypes and precore and core promoter mutations affecting HBV e antigen expression in Taiwan J Clin Microbiol 43 2005 6000 6006
31. C.H. Chen, C.M. Lee, S.N. Lu, C.S. Changchien, J.C. Wang, and J.H. Wang et al. Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy J Hepatol 44 2006 76 82
32. C.H. Chen, C.M. Lee, C.H. Hung, T.H. Hu, J.H. Wang, and J.C. Wang et al. Clinical significance and evolution of core promoter and precore mutations in HBeAg-positive patients with HBV genotype B and C: a longitudinal study Liver Int 27 2007 806 815
33. C.M. Lee, C.H. Chen, S.N. Lu, H.D. Tung, W.J. Chou, and J.H. Wang et al. Prevalence and clinical implications of hepatitis B virus genotypes in southern Taiwan Scand J Gastroenterol 1 2003 95 101
34. T. Chen, Y. He, X. Liu, Z. Yan, K. Wang, and H. Liu et al. Nucleoside analogues improve the short-term and long-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure Clin Exp Med 12 2012 159 164
35. Y.L. Cui, F. Yan, Y.B. Wang, X.Q. Song, L. Liu, and X.Z. Lei et al. Nucleoside analogue can improve the long-term prognosis of patients with hepatitis B virus infection-associated acute on chronic liver failure Dig Dis Sci 55 2010 2373 2380
36. P. Marcellin, E.J. Heathcote, M. Buti, E. Gane, R.A. de Man, and Z. Krastev et al. Tenofovir disoproxil fumarate vs. adefovir dipivoxil for chronic hepatitis B N Engl J Med 359 2008 2442 2455
37. H. Garg, S.K. Sarin, M. Kumar, V. Garg, B.C. Sharma, and A. Kumar Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure Hepatology 53 2011 774 780
38. M.F. Yuen, E. Sablon, C.K. Hui, T.M. Li, H.J. Yuan, and D.K. Wong et al. Prognostic factors in severe exacerbation of chronic hepatitis B Clin Infect Dis 36 2003 979 984
39. L.J. Sun, J.W. Yu, Y.H. Zhao, P. Kang, and S.C. Li Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure J Gastroenterol Hepatol 25 2010 583 590
40. P.L. Tseng, S.N. Lu, H.D. Tung, J.H. Wang, C.S. Changchien, and C.M. Lee Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis J Viral Hepat 12 2005 386 392
41. T. Imamura, O. Yokosuka, T. Kurihara, T. Kanda, K. Fukai, and F. Imazeki et al. Distribution of hepatitis B viral genotypes and mutations in the core promoter and precore regions in acute forms of liver disease in patients from Chiba, Japan Gut 52 2003 1630 1637
42. R.N. Chien, Y.F. Liaw, and M. Atkins Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group Hepatology 30 1999 770 774